PLX 51107

Drug Profile

PLX 51107

Alternative Names: PLX-51107

Latest Information Update: 12 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Plexxikon
  • Class Antineoplastics; Small molecules
  • Mechanism of Action BRD4-protein-inhibitors; Proto oncogene protein c-myc inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 12 Jul 2018 Chemical structure information added
  • 01 Jun 2018 Efficacy, safety and pharmacokinetics data from a phase I trial in Solid tumours, Acute myeloid leukaemia and Myelodysplastic syndromes presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 15 Sep 2017 MD Anderson Cancer Center and Daiichi Sankyo plans phase I and phase II trials for Acute myeloid leukemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top